Isabella Lurje

Interested in liver immunology in cancer & transplantation
Postdoc @ Charité Berlin

[Journal of Hepatology @JHepatology]

📌In our March issue

Assessment of liver graft quality during hypothermic oxygenated perfusion: The first international validation study

Read it here👉https://t.co/llsZNLf6em

#LiverTwitter

[roypounder.apt @APandT]

Read "Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Impacts Long-Term Outcomes After Curative-Intent Surgery for Hepatocellular Carcinoma" via open access https://t.co/XJhAoUPlcu
#livertwitter #MASLD #HCC

[EASLnews @EASLnews]

The EASL #LiverCancerSummit 2025 kicks off in a few days, bringing together leading experts and young investigators in Paris & online!

One of the highlights? The Young Investigators Poster Tour—a dynamic ePoster session featuring research from emerging scientists in the field of liver cancer.

🗓 Date: Friday, 21 February 2025
🕑 Time: 14:00 - 14:30 CET

📅 Save the session to your calendar & stay tuned!
https://t.co/BOrePXwH3l

@rirmacias @AleksanderKrag @RuiCastroHD @DebbieShawcros1 @aelsharkawy75 @FabioPiscaglia

[Isabella Lurje @ILurje]

@RWTH @C_V_Schneider @AveFoundation @UniklinikAachen Congratulations! 🎈🎈🎈

[CMGH @AGA_CMGH]

Did you read the 17-4 Editor's Essential Reading? If so, check out the corresponding editorial, which discusses how the interleukin 33–T helper 2 cell axis promotes human liver #fibrosis. 🔗https://t.co/UnuroVyUyP

🖋️Isabella Lurje and Frank Tacke

[Linda Hammerich @Flt3Linda]

Here we go! Looking forward to 4 jam-packed days of the latest research in #immunology at #ECI2024 @Irishimmunology @EFIS_Immunology

[Isabella Lurje @ILurje]

@C_V_Schneider Congratulations! Well-deserved 🎉

[Hepatology Communications @HepCommJournal]

��� New follow-up data from the HOPE-ECD-DBD RCT looks at the long-term outcomes of #HOPE treated allografts in #liver transplantation‼️   

💡Machine perfusion may reduce late-onset morbidity and improve graft survival in ECD livers‼️
#LiverTwitter
https://t.co/yHmi6mOBdo

[Linda Hammerich @Flt3Linda]

You can now find this as a technical note in Cytometry Part A: https://t.co/yVJmY2Hjen
We found some surprising differences between commercially available compensation beads 🎆

[Elliot Tapper @ebtapper]

Pumps have changed transplant forever

Long term follow-up after an RCT of HOPE

Open access https://t.co/170pjKm7U3
#livertwitter @HepCommJournal

[Georg Lurje @glurje]

First RCT data on long-term outcomes after hypothermic oxygenated machine perfusion (HOPE) in liver transplantation out now in @Hepcommjournal, showing lower incidence of late-onset complications & improved graft survival in the HOPE group.

https://t.co/jukJdseIvc

[Isabella Lurje @ILurje]

@C_V_Schneider @Academics @UniklinikAachen @RWTH @KM_Schneider1 @Dhv Congratulations! 🎉

[Georg Lurje @glurje]

Wir suchen Verstärkung für unser Team an der @ChariteBerlin & @organ_recovery und freuen uns auf Bewerbungen.

Studienkoordinatorin / Studienkoordinator (d/w/m) Chirurgische Klinik DM.219.23: Charité https://t.co/YdPGOTJGsa

[Isabella Lurje @ILurje]

🔬We analyzed graft-effluent leucocytes during hypothermic oxygenated and normothermic liver machine perfusion in this letter, now published in @Jhepatology
https://t.co/lhpQFK2Ch2
@organ_recovery @glurje @Tacke_lab @Flt3Linda @ChariteBerlin

[Charité - Universitätsmedizin Berlin @ChariteBerlin]

Die vierteilige Doku-Serie zeigt Betroffene & das medizinische Personal der #CharitéBerlin im Wettlauf gegen die Zeit. Unter ihnen: Prof. Georg Lurje, Leitender Oberarzt in der Chirurgischen Klinik am Campus Virchow-Klinikum. Copyright: rbb / DOCDAYS Productions. @glurje

[EASLnews @EASLnews]

⌛ Every 30 seconds, we lose someone to viral hepatitis, causing 1.34 million deaths worldwide annually.

It is the leading cause of primary liver cancer, making it crucial to act against this silent killer ☠️ .

Read more! 🔗 https://t.co/tqAYawtrMp

@EASLedu @EASLEUAffairs

[Isabella Lurje @ILurje]

📍Vienna Airport
So excited to be here! #EASLCongress

[EASLnews @EASLnews]

🌍Today is International #NASHDay!

At EASL, we are joining @globalliver to raise awareness about #NASH!
Explore the resources to learn about relevant #NASH topics – for both patients & clinicians.

👉https://t.co/bkeIQVs7cW
👉Learn more: https://t.co/U38qVbUtGY
#StepUpforNASH

[Tacke Lab @Tacke_lab]

What are the mechanisms of fibrosis across organs and disease etiologies?

💡Our latest review examines the underlying processes and resulting therapeutic opportunities. @ILurje

https://t.co/2YGF6uGIsA